OS Therapies (OSTX) said Wednesday it closed the acquisition of listeria-based cancer immunotherapy assets of Advaxis Immunotherapies from Ayala Pharmaceuticals.
The biopharmaceutical company said it has acquired clinical, preclinical, and intellectual property assets, including immunotherapy programs for human papilloma virus-associated cancers, non-small cell lung cancer, and prostate cancer.
OS Therapies said it is targeting the approval of its OST-HER2 immunotherapy candidate for fully resected, lung metastatic osteosarcoma by the end of 2025.
It also said that new manufacturing-based intellectual property protects the listeria-based immunotherapy platform and cancer immunotherapy candidates through 2040.
Price: 1.25, Change: -0.06, Percent Change: -4.58
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.